VTN and Huntington disease: To determine if changes in complement protein levels or activity can be detected in the CSF of premanifest HD patients and, if so, whether they are associated with established measures of disease burden, we developed assays to measure complement cascade proteins and their activation fragments (Extended Data Fig. 1k–m).